Go to the STIEFEL® Laboratories, Inc. Home   Website index   Contact   German version 
Home
BIOPSY PUNCH skin punches
CURETTE ring curettes
Biopsy techniques
Curettage techniques
Information on the skin biopsy
STIEFEL World website
Contact
Show Information about BIOPSY PUNCH skin punches Show Information about CURETTE ring curettes

 

Information on the skin biopsy

Selecting the biopsy technique

Partial biopsy of malignant tumours

Depending on the size and site of the tumour, as well as the degree of confidence in the clinical diagnosis, a primary excision biopsy is not always sensible. For example, a large, tough basal-cell carcinoma on the face can simulate a fibrous birthmark or a ruptured cyst, and a melanoma may simulate a seborrhoeic keratosis. Primary excision with a plastic covering of the blemish would in such cases amount to a treatment error.

For diagnosis confirmation, partial biopsies may therefore be required; these should be performed as shave biopsies in the case of superficial tumours, and with the scalpel or as a spindle biopsy in cases of profound tumours. This allows a portion of tumour that is as large as possible in the biopsates, with an amount of surrounding tissue that is as small as possible. Deep biopsies are indicated if the tumours impress clinically by being tubercles, and if the lower half of the dermis appears to be infiltrated (kerato-acanthoma, Merkel-cell carcinoma, etc.) Profound biopsies are also preferable in regions with particularly thick epithelium, especially the inner surfaces of hands and soles of feet, where superficial shave biopsies frequently record only the horny layer.(2) In the case of large ulcerated growths, a spindle biopsy from the edge of the ulcer should be performed, as near to vertical to the ulcer as possible, including small portions of the ulcer and surrounding skin.

Shave biopsies are to be recommended in early-stage epithelial tumours (e.g. Morbus Bowen, solar keratosis). Also in partial biopsies of malign melanoma, it is a case of recording as large a superficial tumour portion as possible, since the changes that are critical for the histo-pathological diagnosis are to be found in the epithelium (such as melanocytes in higher layers of epidermis, confluence of joints, differing shapes and sizes of joints, unclear demarcation of individual melanocytes at the periphery). If melanoma for diagnosis confirmation cannot be removed completely, then a broad shave biopsy, including the side edge of a tumour, is indicated. The fear once raised that a partial biopsy could harm the prognosis of the melanoma has been refuted conclusively in numerous studies.(13) Nonetheless, shave biopsies where there is suspected melanoma should be carried out only in exceptional circumstances, since assessment of the overall structure of a pigment-cell tumour is vital for diagnosis.(2)

In superficial tumours, punch biopsies have the drawback compared with the shave biopsy that significantly fewer tumours are recorded for any given volume of biopsy. Punches from a pigment-cell tumour are frequently inadequate for any confident diagnosis. In a retrospective study of 1784 partial biopsies on malign melanoma, there was sufficient material for a definitive diagnosis in only 32% of punch biopsies, whereas the figure was 86% in the case of shave biopsies.(21) In the case of punches taken from the centre of a superficial basalioma, it even turned out that no tumour was evident at all, due to the irregular extent and focal regression zones. Use of the sharp spoon is also contra-indicated in cases of suspected malignant tumours, due to tissue fragmentation. Nonetheless, if malignant tumours are curetted, the Stratum papillare should also be recorded, in order that, for example, where there are solar keratoses, an invasive growth can in all probability be ruled out. When using the sharp ring curette, this is generally the case.

 next page "The contingent relation between biopsy size and differential clinical diagnosis"
 previous page "Excision biopsy of malignant tumours"

 back to the Index of contents

 

Imprint    Privacy policy    Disclaimer

© Stiefel Laboratorium GmbH. Ein Unternehmen der GSK-Gruppe. All rights reserved.
Last Update: 10.08.2009.